Increased Risk of Bladder Cancer for Users of Actos
If you, or someone you know, has used Actos®, you are at an increased risk for bladder cancer
In June of this year, the drug Actos was being taken down from drugstore counters in France and doctors in Germany have been instructed not to prescribe Actos to their patients. These countries’ actions are as a result of recent studies indicating an increased rate in bladder cancer for users who are using Actos to treat their Type 2 Diabetes.
On June 15, 2011, the FDA issued an urgent health warning to users and prescribers of the drug Actos. This warning served as acknowledgment of the new statistical data indicating that there can be up to a 40% increase in risk for bladder cancer for patients treating their Diabetes Type II with Actos. There was an additional correlation suggesting that the risk of bladder cancer increases proportionately with higher dosages and longer courses of treatment with Actos.
In a further regulatory action, the FDA now requires that these above findings and additional risks be included in warnings attached to the drug packaging and future marketing materials.
The FDA is continuing to scrutinize additional studies as it monitors the long term health effects of Actos (Pioglitazone). Currently, Actos remains available to consumers in the United States regardless of the newly publicized risks.
Potential side effects caused by these drugs include:
- Abdominal pain
- Back pain
- Blood in urine
- Pain in urination
- Urination urgency
- Loss of appetite/weight
- Bladder cancer
If you or a loved one were prescribed Actos to treat your Type II- Diabetes and have been diagnosed with bladder cancer or have experienced any of the above listed symptoms, please call (888) 391-8244 or contact us